Among its four molecular subtypes, TNBC and HER2-positive types are the most aggressive, with high invasiveness, poor prognosis, and significant mortality—TNBC alone accounting for 83% of breast cancer deaths [3]. Here, ERBB2 is linked to breast cancer.